Roche launches GS Junior System benchtop DNA sequencing platform for life science research

Roche (Pink Sheets:RHHBY) (SWX:RO) (SWX:ROG), announced today the global launch of the GS Junior System, the company's new benchtop next-generation DNA sequencing platform for life science research. The GS Junior System, developed by 454 Life Sciences, a Roche company, provides an integrated sequencing and bioinformatics solution, all in a size that is no bigger than a typical desktop laser printer. Due to its size, efficiency and price competitiveness, thousands of small and medium sized research laboratories worldwide will now have access to Roche's state-of-the-art sequencing capabilities at an affordable price.

“Putting the GS Junior System into hands of researchers worldwide will help to expand our knowledge of the genetic causes and molecular basis of diseases thereby contributing to the development of personalized healthcare.”

The GS Junior System offers solutions for DNA sequencing in nearly every field of biological research including human population genetics, agricultural and environmental genomics and particularly for research in the area of human health. The system is ideally suited for research labs that require targeted sequencing of genomic regions associated with diseases such as diabetes and cancer, whole microbial genome sequencing, metagenomic analysis, as well as novel pathogen detection. That technology also offers significant advantages over current standards in many areas of medical research, such as in tissue matching for transplantation and HIV drug resistance detection.

"Roche has a proven track record of delivering innovative solutions in both life science research and diagnostics. With its fast turn around time and high sensitivity we expect the GS Junior System to provide significant medical value in future diagnostic applications," said Daniel O'Day, Chief Operating Officer of Roche Diagnostics. "Putting the GS Junior System into hands of researchers worldwide will help to expand our knowledge of the genetic causes and molecular basis of diseases thereby contributing to the development of personalized healthcare."

DNA sequencing is a large growth opportunity, particularly in the areas of oncology where elucidation of new mutations and gene rearrangements offer greater insights into disease mechanisms and potential areas for drug discovery. Currently, the global sequencing business is worth over one billion Swiss francs, with substantial double digit growth expected for the next several years.